| Name | Title | Contact Details |
|---|
Remedent is a El Segundo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Xoran Technologies, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Mid-Island Medical Supply is a Wantagh, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Propeller is the leading digital platform for respiratory health management.Through sensors, mobile apps and services, Propeller helps reduce the cost of care while delivering better quality of life for individuals with chronic respiratory disease. Backed by Safeguard Scientifics, Social Capital, California HealthCare Foundation and other investors, Propeller Health is now working with organizations like Dignity Health, Wyckoff Heights Medical Center, Amerigroup Florida and the City of Louisville. Company recognition includes TEDMED Innovation Showcase, White House Champion of Change and Bluetooth Breakthrough Product awards. The system has been featured in The Economist, Washington Post, Fast Company, Wired and Scientific American.
Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific`s Reveal™ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specific`s unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specific`s system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing.